JaxBio Technologies News
2 articles
growth-positive
JaxBio Technologies Secures €2.5M Grant from European Innovation Council Accelerator
JaxBio Technologies, a medical diagnostics company based in Netanya, Israel, has secured a €2.5M grant from the European Innovation Council (EIC) Accelerator. The grant includes the option for future blended financing, with a potential additional €9.1M from the EU and a matching €9.1M from other investors. The company plans to use the funds to expand clinical programs and develop its diagnostics platform to create a blood test for making lung cancer detection and management simpler, quicker, and highly accurate.
InvestmentExpand
growth-positive
Israeli Startup JaxBio Snags €8.5M EU Grant to Support Creation of Array-Based Cancer Tests
JaxBio Technologies, an Israeli company, has received an €8.5 million EU Horizon Europe grant to support the development of a new array-based platform for diagnosing hematological malignancies. The project, called Sanguine, aims to develop a liquid biopsy-based test that can classify a set of hematological malignancies by detecting epigenetic markers in peripheral blood cells and cell-free DNA. The test will use a custom microarray called the HemaChip. The funding will pave the way for the eventual deployment of the test in clinical settings. JaxBios technology is a cost-effective and scalable alternative to sequencing and PCR. The company is also working on a project called Base6 to develop a custom microarray targeted to 5-hydroxymethylcytosine. JaxBio is planning a series A round in the near future.
InvestmentPartnersExpand
